Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease

Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, Innsbruck, AustriaAbstract: The aim of this article is to provide a short review of the most relevant pharmacological and clinical data on pramipexole extended release (ER) as well as to address the c...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hametner EM, Seppi K, Poewe W
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Pramipexole
Parkinson's Disease
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/9824c32fbc7941e8b9b5342659a32ae5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9824c32fbc7941e8b9b5342659a32ae5
record_format dspace
spelling oai:doaj.org-article:9824c32fbc7941e8b9b5342659a32ae52021-12-02T03:55:22ZRole and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease1178-1998https://doaj.org/article/9824c32fbc7941e8b9b5342659a32ae52012-03-01T00:00:00Zhttps://www.dovepress.com/role-and-clinical-utility-of-pramipexole-extended-release-in-the-treat-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, Innsbruck, AustriaAbstract: The aim of this article is to provide a short review of the most relevant pharmacological and clinical data on pramipexole extended release (ER) as well as to address the clinical utility and potential advantages of a once-daily formulation especially in the treatment of early Parkinson's disease (PD). Pramipexole is widely established as a symptomatic treatment in early as well as advanced PD. The development of an ER formulation, with stable pramipexole plasma concentration over 24 hours, now offers a bioequivalent once-daily alternative. Double-blind randomized controlled trials in early and advanced PD, have established noninferiority of pramipexole ER compared with immediate release as well as superiority of both formulations over placebo. The overnight switch from the standard to the once-daily formulation was shown to be successful in >80% of patients without requiring any dose adjustments. Potential benefits of the prolonged-release design, which have not yet been formally demonstrated in the pivotal trial program, include improved compliance and a potential for better symptomatic control, particularly in patients with early disease that can be managed with monotherapy.Keywords: pramipexole, Parkinson's disease, extended release, compliance, controlHametner EMSeppi KPoewe WDove Medical PressarticlePramipexoleParkinson's DiseaseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 7, Pp 83-88 (2012)
institution DOAJ
collection DOAJ
language EN
topic Pramipexole
Parkinson's Disease
Geriatrics
RC952-954.6
spellingShingle Pramipexole
Parkinson's Disease
Geriatrics
RC952-954.6
Hametner EM
Seppi K
Poewe W
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
description Eva-Maria Hametner, Klaus Seppi, Werner PoeweDepartment of Neurology, Innsbruck Medical University, Innsbruck, AustriaAbstract: The aim of this article is to provide a short review of the most relevant pharmacological and clinical data on pramipexole extended release (ER) as well as to address the clinical utility and potential advantages of a once-daily formulation especially in the treatment of early Parkinson's disease (PD). Pramipexole is widely established as a symptomatic treatment in early as well as advanced PD. The development of an ER formulation, with stable pramipexole plasma concentration over 24 hours, now offers a bioequivalent once-daily alternative. Double-blind randomized controlled trials in early and advanced PD, have established noninferiority of pramipexole ER compared with immediate release as well as superiority of both formulations over placebo. The overnight switch from the standard to the once-daily formulation was shown to be successful in >80% of patients without requiring any dose adjustments. Potential benefits of the prolonged-release design, which have not yet been formally demonstrated in the pivotal trial program, include improved compliance and a potential for better symptomatic control, particularly in patients with early disease that can be managed with monotherapy.Keywords: pramipexole, Parkinson's disease, extended release, compliance, control
format article
author Hametner EM
Seppi K
Poewe W
author_facet Hametner EM
Seppi K
Poewe W
author_sort Hametner EM
title Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
title_short Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
title_full Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
title_fullStr Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
title_full_unstemmed Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease
title_sort role and clinical utility of pramipexole extended release in the treatment of early parkinson's disease
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/9824c32fbc7941e8b9b5342659a32ae5
work_keys_str_mv AT hametnerem roleandclinicalutilityofpramipexoleextendedreleaseinthetreatmentofearlyparkinson39sdisease
AT seppik roleandclinicalutilityofpramipexoleextendedreleaseinthetreatmentofearlyparkinson39sdisease
AT poewew roleandclinicalutilityofpramipexoleextendedreleaseinthetreatmentofearlyparkinson39sdisease
_version_ 1718401568995278848

Ejemplares similares